Parkin, PINK1 and DJ1 as possible modulators of mTOR pathway in ganglioglioma

References

• Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114:97–109.
   PubMed Web of Science ®Google Scholar
• Kang DH, Lee CH, Hwang SH, et al. Anaplastic ganglioglioma in a middle-aged woman: a case report with a review of the literature. J Korean Med Sci. 2007 Sep; Suppl:S139–S144, 22.
   Google Scholar
• Yano H, Saigoh C, Nakayama N, et al. Mixed neuronal-glial tumor in the temporal lobe of an infant: a case report. Diagn Pathol. 2013;2(8):164.
   Google Scholar
• Im SH, Chung CK, Cho BK, et al. Intracranial ganglioglioma: preoperative characteristics and oncologic outcome after surgery. J Neurooncol. 2002;59(2):173–183.
   PubMed Web of Science ®Google Scholar
• Dudley RW, Torok MR, Gallegos DR, et al. Pediatric low grade ganglioglioma: epidemiology, treatments, and outcome analysis on 348 children from the surveillance, epidemiology, and end results database. Neurosurgery. 2015;76(3):313–319.
   PubMed Web of Science ®Google Scholar
• Hanai S, Okazaki K, Fujikawa Y, et al. Hemifacial seizures due to ganglioglioma of cerebellum. Brain Dev. 2010;32:499–501.
   PubMed Web of Science ®Google Scholar
• Harvey AS, Jayakar P, Duchowny M, et al. Hemifacial seizures and cerebellar ganglioglioma; an epilepsy syndrome of infancy with seizures of cerebellar origin. Ann Neurol. 1996;40(1):91–98.
   PubMed Web of Science ®Google Scholar
• Blümcke I, Sarnat HB, Coras R. Surgical neuropathology of focal epilepsies. Montrouge: John Libbey Eurotext; 2015. p. 54–61.
   Google Scholar
• Kim SD, Kim JH, Lee CY, et al. Ganglioglioma in brainstem: case report and a review of literatures. J Korean Neurosurg Soc. 2014;55(3):164–166.
   PubMed Web of Science ®Google Scholar
• Murakami T, Koyanagi I, Kaneko T, et al. Intramedullary spinal cord ganglioglioma presenting as hyperhidrosis: unique symptoms and magnetic resonance imaging findings: case report. J Neurosurg Spine. 2013;18(2):184–188.
   PubMed Web of Science ®Google Scholar
• Saad AF, Layton KF, Finn SS, et al. Ganglioglioma and migraine headache. Proc Bayl Univ Med Cent. 2014;27(3):215–216.
   PubMedGoogle Scholar
• Qin Q, Tabbara AK, Delalle I, et al. An enigmatic brainstem posterior fossa ganglioglioma in an adult. Int J Neurosci. 2014;124(9):704–706.
   PubMed Web of Science ®Google Scholar
• Lagares A, Gómez PA, Lobato RD, et al. Ganglioglioma of the brainstem: report of three cases and review of the literature. Surg Neurol. 2001;56(5):315–322.
   PubMedGoogle Scholar
• Huang C, Li H, Chen M, et al. Factors associated with preoperative and postoperative epileptic seizure in patients with cerebral ganglioglioma. Pak J Med Sci. 2014;30(2):245–249.
   PubMed Web of Science ®Google Scholar
• Samadani U, Judkins AR, Akpalu A, et al. Differential cellular gene expression in ganglioglioma. Epilepsia. 2007;48(4):646–653.
   PubMed Web of Science ®Google Scholar
• Song JY, Kim JH, Cho YH, et al. Treatment and outcomes for gangliogliomas: a single-center review of 16 patients. Brain Tumor Res Treat. 2014;2(2):49–55.
   PubMedGoogle Scholar
• Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell. 2007;12(1):9–22.
   PubMed Web of Science ®Google Scholar
• Dowling RJO, Topisirovic I, Fonseca BD, et al. Dissecting the role of mTOR: lessons from mTOR inhibitors. Biochimica et Biophysica Acta. 2010;1804:433–439.
   PubMed Web of Science ®Google Scholar
• Becker AJ, Löbach M, Klein H, et al. Mutational analysis of TSC1 and TSC2 genes in gangliogliomas. Neuropathol Appl Neurobiol. 2001;27(2):105–114.
   PubMed Web of Science ®Google Scholar
• Rak B, Szlufik S, Grajkowska W, et al. Upregulation of mitogen-activated protein kinase in ganglioglioma. Folia Neuropathol. 2013;51(4):283–289.
   PubMed Web of Science ®Google Scholar
• Boer K, Troost D, Timmermans W, et al. Pi3K-mTOR signaling and AMOG expression in epilepsy-associated glioneuronal tumors. Brain Pathol. 2010;20(1):234–244.
   PubMed Web of Science ®Google Scholar
• del Bufalo F, Carai A, Figà-Talamanca L, et al. Response of recurrent BRAFV600E mutated ganglioglioma to Vemurafenib as single agent. J Transl Med. 2014;12:356.
   PubMed Web of Science ®Google Scholar
• Kawashima M, Suzuki SO, Doh-ura K, et al. alpha-Synuclein is expressed in a variety of brain tumors showing neuronal differentiation. Acta Neuropathol. 2000;99(2):154–160.
   PubMed Web of Science ®Google Scholar
• Trempe JF, Fon EA. Structure and function of parkin, PINK1, and DJ-1, the three musketeers of neuroprotection. Front Neurol. 2013;4:38.
   PubMed Web of Science ®Google Scholar
• Lonskaya I, Desforges NM, Hebron ML, et al. Ubiquitination increases parkin activity to promote autophagic α-synuclein clearance. PLoS One. 2013;8(12):e83914.
   PubMed Web of Science ®Google Scholar
• Inzelberg R, Jankovic J. Are Parkinson disease patients protected from some but not all cancers? Neurology 2007;69:1542–1550.
   PubMed Web of Science ®Google Scholar
• Yeo CW, Ng FS, Chai C, et al. Parkin pathway activation mitigates glioma cell proliferation and predicts patient survival. Cancer Res. 2012;72(10):2543–2553.
   PubMed Web of Science ®Google Scholar
• Vavougios G, Kerenidi T, Tsilioni I, et al. Pleural effusion levels of DJ-1 are increased in elderly lung cancer patients with malignant pleural effusions. Redox Rep. 2015;20(6):254–258.
   PubMed Web of Science ®Google Scholar
• Liu S, Long G, Wei H, et al. DJ-1 knockdown inhibits growth and xenograft-induced tumor generation of human hepatocellular carcinoma cells. Oncol Rep. 2015;33(1):201–206.
   PubMed Web of Science ®Google Scholar
• Lev N, Barhum Y, Lotan I, et al. DJ-1 knockout augments disease severity and shortens survival in a mouse model of ALS. PLoS One. 2015;10(3):e0117190.
   PubMed Web of Science ®Google Scholar
• Li X, Geng J, Liu J. Adiponectin offeres protection against L166P mutant DJ-1-induced neuronal cytotoxicity Mediatel by APPL1-dependent AMPK activation. Int J Neurosci. 2014;124(5):350–361.
   PubMed Web of Science ®Google Scholar
• Kim JM, Jang HJ, Choi SY, et al. DJ-1 contributes to adipogenesis and obesity-induced inflammation. Sci Rep. 2014;4:4805.
   PubMed Web of Science ®Google Scholar
• Dave KD, De Silva S, Sheth NP, et al. Phenotypic characterization of recessive gene knockout rat models of Parkinson's disease. Neurobiol Dis. 2014;70:190–203.
   PubMed Web of Science ®Google Scholar
• Deas E, Piipari K, Machhada A, et al. PINK1 deficiency in β-cells increases basal insulin secretion and improves glucose tolerance in mice. Open Biol. 2014;4:140051.
   PubMed Web of Science ®Google Scholar
• Bueno M, Lai YC, Romero Y, et al. PINK1 deficiency impairs mitochondrial homeostasis and promotes lung fibrosis. J Clin Invest. 2015;125(2):521–538.
   PubMed Web of Science ®Google Scholar
• Patel AS, Song JW, Chu SG, et al. Epithelial cell mitochondrial dysfunction and PINK1 are induced by transforming growth factor-beta1 in pulmonary fibrosis. PLoS One. 2015;10(3):e0121246.
   PubMed Web of Science ®Google Scholar
• Devine MJ, Plun-Favreau H, Wood NW. Parkinson's disease and cancer: two wars, one front. Nat Rev Cancer. 2011;11(11):812–823.
   PubMed Web of Science ®Google Scholar
• Ikeuchi K, Marusawa H, Fujiwara M, et al. Attenuation of proteolysis-mediated cyclin E regulation by alternatively spliced parkin in human colorectal cancers. Int J Cancer. 2009;125(9):2029–2035
   PubMed Web of Science ®Google Scholar
• Tay SP, Yeo CW, Chai C, et al. Parkin enhances the expression of cyclin-dependent kinase 6 and negatively regulates the proliferation of breast cancer cells. J Biol Chem. 2010;285(38):29231–29238.
   PubMed Web of Science ®Google Scholar
• Kim RH, Peters M, Jang Y, et al. DJ-1, a novel regulator of the tumor suppressor PTEN. Cancer Cell. 2005;7(3):263–273.
   PubMed Web of Science ®Google Scholar
• Rakovic A, Shurkewitsch K, Seibler P, et al. Phosphatase and tensin homolog (PTEN)-induced putative kinase 1 (PINK1)-dependent ubiquitination of endogenous parkin attenuates mitophagy: study in human primary fibroblasts and induced pluripotent stem cell-derived neurons. J Biol Chem. 2013;288(4):2223–2237.
   PubMed Web of Science ®Google Scholar
• Kato I, Maita H, Takahashi-Niki K, et al. Oxidized DJ-1 inhibits p53 by sequestering p53 from promoters in a DNA-binding affinity-dependent manner. Mol Cell Biol. 2013;33(2):340–359.
   PubMed Web of Science ®Google Scholar
• Soffer D, Umansky F, Goldman JE. Ganglioglioma with neurofibrillary tangles (NFTs): neoplastic NFTs share antigenic determinants with NFTs of Alzheimer's disease. Acta Neuropathol. 1995;89(5):451–453.
   PubMed Web of Science ®Google Scholar
• Olsen JH, Friis S, Frederiksen K, et al. Atypical cancer pattern in patients with Parkinson's disease. Br J Cancer. 2005;92(1):201–205.
   PubMed Web of Science ®Google Scholar
• Ariga H. Common mechanisms of onset of cancer and neurodegenerative diseases. Biol Pharm Bull. 2015;38(6):795–808.
   PubMed Web of Science ®Google Scholar
• Veeriah S, Taylor BS, Meng S, et al. Somatic mutations of the Parkinson's disease-associated gene PARK2 in glioblastoma and other human malignancies. Nat Genet. 2010;42(1):77–82.
   PubMed Web of Science ®Google Scholar
• Narendra DP, Jin SM, Tanaka A, et al. PINK1 is selectively stabilized on impaired mitochondria to activate parkin. PLoS Biol. 2010;8(1):e1000298.
   PubMed Web of Science ®Google Scholar
• Ariga H, Takahashi-Niki K, Kato I, et al. Neuroprotective function of DJ-1 in Parkinson's disease. Oxid Med Cell Longev. 2013;2013:683920.
   PubMed Web of Science ®Google Scholar
• Prakash V, Batanin JR, Guzman MA, et al. Malignant transformation of a desmoplastic infantile ganglioglioma in an infant carrier of a nonsynonymous TP53mutation. Pediatr Neurol. 2014;51(1):138–143.
   PubMed Web of Science ®Google Scholar
• Yuzuru Imai. Mitochondrial regulation by PINK1-Parkin signaling. ISRN Cell Biology. 2012;2012:15, ID 926160.
   Google Scholar
• Erekat NS. Apoptotic mediators are upregulated in the skeletal muscle of chronic/progressive mouse model of Parkinson's disease. Anat Rec (Hoboken). 2015;298(8):1472–1478.
   PubMedGoogle Scholar
• Sarnat HB, Flores-Sarnat L. Infantile tauopathies: hemimegalencephaly; tuberous sclerosis complex; focal cortical dysplasia 2; ganglioglioma. Brain Dev. 2015;37(6):553–562
   PubMed Web of Science ®Google Scholar